secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001193125-25-004142
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam provides 2024-2025 update: Phase 3 data, $835M cash, EMA filing in 2H25
--------------------------------------------------------------------------------

- BROADWAY Phase 3 met primary endpoint: 33% LS mean LDL-C reduction (p<0.0001); exploratory MACE reduction of 21%.
- Unaudited year-end cash of $835 million; funds operations through PREVAIL CVOT readout and potential commercial launch.
- Menarini to submit EMA filing for obicetrapib in 2H2025; additional Phase 3 data presentations planned throughout 2025.
- VINCENT Phase 2 trial exploring obicetrapib +/- PCSK9i on Lp(a) expected to complete in 2H2025.
- USPTO issued composition-of-matter patent for obicetrapib, providing IP protection in US until July 2043.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312525004142/0001193125-25-004142-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312525004142/d837783d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-004142

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer